Showing results (201-210 of 237) with videos related to
Sort By:
Pageof 24
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.Human Genetics|May 21, 2011
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriersKate M Im, Tomas Kirchhoff, Xianshu Wang, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 7, 2011
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, et al.Plos Genetics|April 2, 2013
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskMia M Gaudet, Karoline B Kuchenbaecker, Joseph Vijai, et al.Human Molecular Genetics|August 7, 2009
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Olga M Sinilnikova, Lesley McGuffog, et al.Plos One|July 28, 2016
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersElena Vigorito, Karoline B Kuchenbaecker, Jonathan Beesley, et al.Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.Journal of the National Cancer Institute|December 21, 2010
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriersSusan J Ramus, Christiana Kartsonaki, Simon A Gayther, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.Pageof 24